EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine

Shohei Yamamoto, Yusuke Oshiro, Natsumi Inamura, Takashi Nemoto, Kumi Horii, Kaori Okudera, Maki Konishi, Mitsuru Ozeki, Tetsuya Mizoue, Haruhito Sugiyama, Nobuyoshi Aoyanagi, Wataru Sugiura und 1 weitere

Clinical Microbiology and Infection · 2023

DOI: 10.1016/j.cmi.2023.05.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Microbiology and Infection, 2023. Verfasst von Shohei Yamamoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan. Electronic add…. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To examine the differences in durability and its determinants of humoral immunity following 2- and 3-dose COVID-19 vaccination. METHODS: Throughout the pandemic, we evaluated the anti-spike IgG antibody titers of 2- and 3-dose mRNA vaccine recipients over time among the staff of a medical and research center in Tokyo. Linear mixed models were used to estimate trajectories of antibody titers from 14 to 180 days after the last immune-conferred event (vaccination or infection) and compare antibody waning rates across prior infection and vaccination status, and across background factors in infection-naïve participants. RESULTS: A total of 6901 measurements from 2964 participants (median age, 35 years; 30% male) were analyzed. Antibody waning rate (percentage per 30 days [95% CI]) was slower after 3 doses (25% [23-26]) than 2 doses (36% [35-37]). Participants with hybrid immunity (vaccination and infection) had further slower waning rates: 2-dose plus infection (16% [9-22]); 3-dose plus infection (21% [17-25]). Older age, male sex, obesity, coexisting diseases, immunosuppressant use, smoking, and alcohol drinking were associated with lower antibody titers, whereas these associations disappeared after 3 doses, except for sex (lower in female participants) and immunosuppressant use. Antibody waned slightly faster in older participants, females, and alcohol drinkers after 2 doses, whereas it did not differ after 3 doses across except sex. DISCUSSION: The 3-dose mRNA vaccine conferred higher durable antibody titers, and previous infection modestly enhanced its durability. The antibody levels at a given time point and waning speed after 2 doses differed across background factors; however, these differences mostly diminished after 3 doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19FemaleHumansMaleAgedAdultAntibodies, ViralImmunosuppressive AgentsRNA, MessengerVaccination

Stichwörter der Autor:innen

DurabilityPrior infectionSARS-CoV-2Spike antibodyVaccination

Substanzen

COVID-19 VaccinesAntibodies, ViralImmunosuppressive AgentsRNA, Messenger

Autor:innen und Institutionen

  • Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: syamamoto@hosp.ncgm.go.jp.
  • Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
  • Infection Control Office, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
  • Infection Control Office, Kohnodai Hospital of the National Center for the Global Health and Medicine, Chiba, Japan.
  • Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.

Zitieren

APA

Yamamoto, S., Oshiro, Y., Inamura, N., Nemoto, T., Horii, K., Okudera, K., Konishi, M., Ozeki, M., Mizoue, T., Sugiyama, H., Aoyanagi, N., Sugiura, W., & Ohmagari, N. (2023). Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2023.05.020

Vancouver

Yamamoto S, Oshiro Y, Inamura N, Nemoto T, Horii K, Okudera K, et al. Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine. Clinical Microbiology and Infection. 2023. doi:10.1016/j.cmi.2023.05.020

BibTeX
@article{Yamamoto2023,
  author = {Yamamoto, Shohei and Oshiro, Yusuke and Inamura, Natsumi and Nemoto, Takashi and Horii, Kumi and Okudera, Kaori and Konishi, Maki and Ozeki, Mitsuru and Mizoue, Tetsuya and Sugiyama, Haruhito and Aoyanagi, Nobuyoshi and Sugiura, Wataru and Ohmagari, Norio},
  title = {Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine},
  journal = {Clinical Microbiology and Infection},
  year = {2023},
  doi = {10.1016/j.cmi.2023.05.020}
}
Kostenlos starten →